Gyre Therapeutics Inc 2024年度报告

SECURITIES AND EXCHANGE COMMISSION (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the year ended December 31, 2024OR2TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission file number: 000-51173 Gyre Therapeutics, Inc. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes"NoIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act.Yes"No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. YesNo" Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).YesNo" Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer"Non-accelerated filer" Accelerated filerSmaller reporting companyEmerging growth company" If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act."Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountingfirm that prepared or issued its audit report.If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements." Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b)."Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes"No The aggregate market value of the voting common stock held by non-affiliates of the registrant (based on the closing price of such stock onThe Nasdaq Capital Market on June 30, 2024, the last business day of the registrant’s most recently completed second fiscal quarter) wasapproximately $83.3 million. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of theoutstanding common stock have been excluded because such persons may be deemed to be affiliates of the registrant. This determination of affiliatestatus is not necessarily a conclusive determination for other purposes. As of March 7, 2025, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 93,612,442,which includes 7,280,230 shares of common stock issued in the name of the registrant to a stock plan administrator of the registrant (see Note 8—Stockholders’ Equity). Gyre Therapeutics, Inc.Annual Report on Form 10-KTABLE OF CONTENTS PART I Item 1.Business............................................................................................................................................5Item 1A.Risk Factors.......................................................................................................................................60Item 1B.Unresolved Staff Comments...........................................................................................................130Item 1C.Cybersecurity....................................................................................................................................130Item 2.Properties..........................................................................................................................................131Item 3.Legal Proceedings............................................................................................................................131Item 4.Mine Safety Disclosures....................................................................